Jacques P. Tremblay

Has grant

Professor

Laval University

Canada

Research Interests

Explore related searches

Professors in Canada Professors in Tissue Engineering Tissue Engineering professors in Canada

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Jacques P. Tremblay is a Professor at Université Laval in Canada. His research focuses on gene editing technologies, particularly Prime Editing and CRISPR/Cas9 delivery strategies, with applications in myopathies and genetic disorders. Recent articles reflect his exploration of therapeutic strategies for conditions such as dysferlinopathy and Friedreich ataxia.

Recent Grants

Grant: Close

Removal of the GAA repeat with the CRISPR/Cas9 system in Friedreich patient cells and in the YG8sR mouse model

Open Date: 2019-03-01

Close Date: 2024-02-01

Articles (15)

Year:

2025

Year:

2025

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (3)

STEVEN Reiken

Assistant Professor

Columbia University Irving Medical Center

UNITED STATES

View details

Kelly Godbout

Université Laval

CANADA

View details

YAOYAO LU

Laval University

CANADA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Jacques P. Tremblay

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (15)

In Vitro Correction of Point Mutations in the DYSF Gene Using Prime Editing

Universal Prime Editing Therapeutic Strategy for RyR1-Related Myopathies: A Protective Mutation Rescues Leaky RyR1 Channel

Emerging Perspectives on Prime Editor Delivery to the Brain

Portrait of Dysferlinopathy: Diagnosis and Development of Therapy

Finding an Appropriate Mouse Model to Study the Impact of a Treatment for Friedreich Ataxia on the Behavioral Phenotype

Removal of the GAA repeat in the heart of a Friedreich’s ataxia mouse model using CjCas9

Limb–Girdle Muscular Dystrophies Classification and Therapies

Prime Editing for Human Gene Therapy: Where Are We Now?

Small-molecule inhibitors of proteasome increase CjCas9 protein stability

Successful Correction by Prime Editing of a Mutation in the RYR1 Gene Responsible for a Myopathy

CRISPR/Cas9 delivery strategies with engineered extracellular vesicles

Prime editing optimized RTT permits the correction of the c.8713C>T mutation in DMD gene

Delivery of RNAs to Specific Organs by Lipid Nanoparticles for Gene Therapy

CRISPR-Cas9 Gene Therapy for Duchenne Muscular Dystrophy

Insertion of the Icelandic Mutation (A673T) by Prime Editing: A Potential Preventive Treatment for Familial and Sporadic Alzheimer's Disease

Collaborators (3)

STEVEN Reiken

Kelly Godbout

YAOYAO LU

Make your next move.